No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract AMLSG 09-09: Adding getuzumab ozogamicin (GO) to intensive therapy for Nucleophosmin1 mutated acute myeloid leukemia (NPM1mut AML) leads to better NPM1mut transcript clearance and a lower replase rate

byKathleen Lau

January 15, 2021

in StudyGraphics

RELATED REPORTS

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

Why Pfizer Is Looking East for Its Next Generation of Cancer Drugs

O and Rh– blood groups may be associated with decreased risk for SARS-CoV-2 infection

RelatedReports

Lessons from real-world implementation of lung cancer screening

Chronic Disease

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

June 9, 2026

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

All Specialties

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

June 8, 2026

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Oncology

Why Pfizer Is Looking East for Its Next Generation of Cancer Drugs

June 4, 2026

Pharma

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

June 3, 2026

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Convalescent plasma may not improve outcomes in Covid-19 patients

SARS-CoV-2 detected on various surroundings of asymptomatic COVID-19 positive infant

Hydroxychloroquine may not prevent Covid-19 after contact exposure

#VisualAbstract: Every-other-day dosing of oral rimegepant is effective for preventive treatment of migraines

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result